A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 12, 2009, Pages 936-941

  Herrera, Larry ^a   Bostrom, Bruce ^b   Gore, Lisa ^c   Sandler, Eric ^d   Lew, Glen ^e   Schlegel, Paul G ^g   Aquino, Victor ^f   Ghetie, Victor ^f   Vitetta, Ellen S ^f   Schindler, John ^f  

^a TEMPLE UNIVERSITY   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c CHILDREN S HOSPITAL   (United States)

^d NEMOURS CHILDREN S CLINIC   (United States)

^e CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Immunotoxins; Pediatric acute lymphoblastic leukemia

Indexed keywords

COMBOTOX; CYCLOSPORIN A; DOPAMINE; IMMUNOTOXIN; STEROID; UNCLASSIFIED DRUG; CD19 ANTIGEN; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RICIN;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANAPHYLAXIS; ANTIBODY DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOGENICITY; MALE; MOUTH DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TOXICITY TESTING; TREATMENT RESPONSE; CASE REPORT; DRUG RESISTANCE; IMMUNOLOGY; INFANT; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD22; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTOXINS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RICIN; TREATMENT OUTCOME;

EID: 73949122603     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181bdf211     Document Type: Article

References (18)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Pezzutto A, Dorken B, Rabinovitch PS, et al. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol. 1987;138:2793-2799.
3. Campana D, Janossy G, Bofill M, et al. Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol. 1985;134: 1524-1530.
4. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993;82:2624-2633.
5. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995;85:3457-3465.
6. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res. 2000;6:1302-1313.
7. Stone MJ, Sausville EA, Fay JW, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgGHD37-dgA, in patients with B-cell lymphoma. Blood. 1996;88: 1188-1197.
8. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991;51:4052-4058.
9. Conry RM, Khazaeli MB, Saleh MN, et al. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J Immunother Emphasis Tumor Immunol. 1995; 18:231-241.
10. Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000;14:853-858.
11. Herrera L, Yarbrough S, Ghetie V, et al. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia. 2003;17:334-338.
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
13. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21:1167-1173.
14. Schindler J, Sausville E, Messmann R, et al. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res. 2001;7:255-258.
15. Michalek J, Collins RH, Durrani HP, et al. Definitive separation of graft-versus-leukemia-and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA. 2003;100:1180-1184.
16. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006;176:705-710.
17. Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006;66:7741-7747.
18. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest. 2007;117:3857-3867.